logo conference-reports

Conference Reports

Educational funding by logo MSD Oncology

LALCA 2019 — Erlotinib+bevacizumab: superior efficacy in advanced NSCLC with EGFR mutations, BIM deletions

Higher objective response rate, PFS vs EGFR inhibitors alone.